OptiNose Inc (NASDAQ:OPTN) was up 3.1% during trading on Monday . The stock traded as high as $6.72 and last traded at $6.55, approximately 14,407 shares were traded during trading. A decline of 94% from the average daily volume of 237,919 shares. The stock had previously closed at $6.35.
Several research analysts have commented on OPTN shares. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Royal Bank of Canada set a $20.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Monday, August 12th. BMO Capital Markets decreased their target price on OptiNose from $26.00 to $24.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Zacks Investment Research downgraded OptiNose from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th. Finally, ValuEngine upgraded OptiNose from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. OptiNose currently has an average rating of “Buy” and an average target price of $21.50.
The firm has a market capitalization of $281.38 million, a P/E ratio of -2.42 and a beta of 0.90. The firm has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $7.95. The company has a debt-to-equity ratio of 1.06, a current ratio of 6.60 and a quick ratio of 6.74.
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of OptiNose by 1,569.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after acquiring an additional 3,766 shares in the last quarter. Stifel Financial Corp purchased a new position in OptiNose in the fourth quarter valued at about $63,000. UBS Asset Management Americas Inc. purchased a new position in OptiNose in the second quarter valued at about $72,000. Susquehanna International Group LLP purchased a new position in OptiNose in the second quarter valued at about $77,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in OptiNose in the second quarter valued at about $78,000. Hedge funds and other institutional investors own 66.81% of the company’s stock.
OptiNose Company Profile (NASDAQ:OPTN)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More: What is meant by holder of record?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.